The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Gilead Sciences; Nektar
Stock and Other Ownership Interests - Gilead Sciences; GlaxoSmithKline; Nektar; Ultragenyx Pharmaceuticals
PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.
 
Daniel A. Vaena
Consulting or Advisory Role - AstraZeneca; Exelixis
Research Funding - Acerta Pharma (Inst); Aeglea Biotherapeutics (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Nektar (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Roche/Genentech (Inst); Tekmira (Inst); Tesaro (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Caris Centers of Excellence
 
Jorge Chaves
Stock and Other Ownership Interests - Abbott Laboratories; Johnson & Johnson; Merck
Research Funding - Calithera Biosciences (Inst); Celgene (Inst); EMD Serono (Inst); Halozyme; Immune Design (Inst); Novartis (Inst); Pfizer (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology
 
Marc Ryan Matrana
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Pfizer; Strata Oncology
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech; Merck; Sirtex Medical
 
A. Eli Gabayan
No Relationships to Disclose
 
Matthew John Riese
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Exelixis; Incyte
Research Funding - Bristol-Myers Squibb; Incyte
 
Daniel C. Cho
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Genentech; Pfizer; Prometheus
 
Mary Ann Tagliaferri
Employment - Nektar
Leadership - Nektar
Stock and Other Ownership Interests - Nektar
Consulting or Advisory Role - Bluebird Bio (I); Nektar (I)
Patents, Royalties, Other Intellectual Property - Nektar
Travel, Accommodations, Expenses - Bluebird Bio (I); Nektar; Nektar (I)
 
Jonathan Zalevsky
No Relationships to Disclose
 
Sunny Xie
No Relationships to Disclose
 
Ute Hoch
Other Relationship - Nektar
 
AHSAN NAQI RIZWAN
Employment - Nektar
Stock and Other Ownership Interests - Nektar
 
Sandra Aung
Employment - Nektar; OncoSec (I)
Leadership - OncoSec (I)
Stock and Other Ownership Interests - Aduro Biotech (I); Nektar; OncoSec (I); Tocagen (I)
 
Michael Imperiale
Employment - Nektar
Stock and Other Ownership Interests - Nektar
 
James K. Schwarz
No Relationships to Disclose